1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Liver Disease Newco Alentis Raises CHF12.5m Series A

 
• By Mike Ward

A syndicate of European VCs commits CHF12.5m to Alentis Therapeutics a Swiss-French start-up with a discovery platform focusing on liver diseases. Lead program is a humanized monoclonal antibody targeting liver fibrosis and hepatocellular carcinoma.

Liver cancer, CT scan upper abdomen.
Advanced liver disease and cancer are major clinical challenges

Swiss venture capital firms BioMedPartners and BB Pureos Bioventures have co-led a CHF12.5m ($12.3m) series A round in Alentis Therapeutics, a Swiss-French newco, that is looking to develop novel therapeutics in advanced liver disease and cancer. Other investors in the syndicate are BPI France, Schroder Adveq and the German High-Tech Gründerfonds. Markus Ewert, formerly CBO at Ablynx NV, has been appointed CEO of the new company, which will be headquartered in Basel, Switzerland with a subsidiary in Strasbourg, France and a branch in Germany.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Lilly Scores With Orforglipron In Diabetes, Generating Excitement For Obesity

 
• By Alaric DeArment

The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.

Ironwood To Consider All Options With Apraglutide Setback In SBS

 
• By Joseph Haas

With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

 
• By Alaric DeArment

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.

More from Therapy Areas

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

Telix Moves TLX101 Forward On Encouraging Early Brain Cancer Data

 
• By Alaric DeArment

The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

 
• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.